News

Jumping the gun on contralateral prophylactic mastectomy?


 

Rates of contralateral prophylactic mastectomy in breast cancer are on the rise, but are clinical indications always present to justify the procedure? Dr. Todd Tuttle discusses the trend and cautions physicians to provide patients with accurate assessments of cancer risk and the procedure's actual effects on life expectancy..

Recommended Reading

Genetic alterations may predict everolimus efficacy
MDedge Hematology and Oncology
ASTRO outlines five radiation oncology practices that should be curtailed
MDedge Hematology and Oncology
Everolimus effective in women with early failure of adjuvant therapy
MDedge Hematology and Oncology
Oral therapy for metastatic breast cancer grows in Medicare patients
MDedge Hematology and Oncology
BMN 673 monotherapy makes splash in BRCA-mutated ovarian, breast cancer
MDedge Hematology and Oncology
Tumor distance from nipple boosts nomogram results
MDedge Hematology and Oncology
Pertuzumab approved as first neoadjuvant treatment for breast cancer
MDedge Hematology and Oncology
False-negative rate for sentinel nodes high after neoadjuvant chemotherapy
MDedge Hematology and Oncology
T-DM1 tops physician’s choice in advanced HER2-positive breast cancer
MDedge Hematology and Oncology
Most data reassure regarding TNF inhibitors and cancer
MDedge Hematology and Oncology